Device/Diagnostics Quarterly Deal Statistics, Q3 2016
A look at financing, M&A and alliance activity July–September 2016
Executive Summary
Q3 medtech financing doubled in dollar volume to $3 billion, with debt offerings again representing the majority of the aggregate; acquisitions totaled $5.3 billion, mainly due to Johnson & Johnson’s $4.3 billion buy of Abbott Medical Optics. Diagnostics financings, which brought in $85 million, continued to decline, but at $5 billion, acquisitions showed a slight increase over the previous quarter, with Danaher’s takeover of Cepheid accounting for most of the M&A volume.
You may also be interested in...
Boston Scientific Buys EndoChoice, Mulls De-FUSEing Potential Weakness
Boston Scientific is making a significant investment in its endoscopy portfolio as it strikes a $210m deal to buy colonoscopy specialist EndoChoice. The Natick, Massachusetts, group added that it will be “evaluating strategic options” for EndoChoice’s Fuse colonoscope.
CVRx Funding Boost Will Sustain Barostim Heart Failure Device To US Launch
US heart failure device manufacturer CVRx has scored a double hit by securing $113 million in funding in this flat investor climate and by being one of the first into the US FDA’s EAP, designed to help innovative technologies get faster access to market. CVRx’s much larger rivals are doubtless watching events with an uneasy mix of interest and concern.
J&J Buys Abbott's Ophthalmics Business For $4bn-Plus
The move to sell Abbott Medical Optics unit comes in the midst of a significant portfolio overhaul by Abbott. The deal will put J&J in the ophthalmic surgery business.